Israel based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced new partnerships with Chinese firms Zhejiang International Group Co., Ltd. and Jianmin International Co., Ltd. These collaborations aim to enhance Teva’s commercial layout in the “One Health” sector, increasing the availability of quality products for Chinese consumers.
Strategic Agreements at the China International Import Expo
During the 7th China International Import Expo, Teva signed strategic cooperation agreements with Zhejiang International Group and Jianmin International, further expanding its commercialization efforts in the health sector and accelerating the introduction of high-quality products for Chinese consumers.
Popular Health Products and Sudocrem® Success
Teva’s health products have been well-received in China, with the classic Irish Sudocrem® being the first health consumer product introduced by Teva in China. Suitable for various skin issues, Sudocrem® was launched in China last year through the Cross-Border E-Commerce (CBEC) channel, with successful flagship stores on Tmall International and JD.com. This year, Sudocrem® has been registered with the National Medical Products Administration (NMPA) in China, becoming a cosmetic product with a “little golden shield” for safe use on children.
Deepening Cooperation with Zhejiang International Group
At the expo, Teva and Zhejiang International Group signed an agreement to further expand channels and increase the accessibility of Sudocrem® (Chinese name: Shu Duo Ke Lei), providing more Chinese consumers with high-quality skin health care options.
Addressing Hair Loss Concerns with Minoxidil
Hair loss is a significant concern among young Chinese people, with epidemiological data showing that one in every five Chinese men suffers from androgenetic alopecia. According to the “2023 China Hair Health Lifestyle Blue Book,” the group of people troubled by hair issues in China is becoming more widespread and younger, with approximately 56% of women and 48% of men facing continuous hair loss.
In the 1970s, minoxidil was found to promote hair regrowth in men and has been safely used for over 40 years, making it the highest recommended treatment in guidelines. Teva successfully registered and launched its hair growth product, Missha High, in Hong Kong a decade ago, and it remains a popular brand there.
Strategic Partnership with Jianmin International
At this year’s expo, Teva brought Missha High, containing the active ingredient minoxidil, to its “first exhibition” in mainland China, offering more options for the treatment of hair loss in China. Teva and Jianmin International have reached a strategic cooperation agreement to integrate resources and collaborate in the CBEC channel, aiming to bring more high-quality products to consumers.
Teva’s Global Health Portfolio and Commitment to China
As a century-old multinational pharmaceutical company, Teva has a rich and diverse product portfolio in the global health sector, helping to heal, alleviate, and prevent various diseases. Many of these products have become long-trusted classics among consumers worldwide, ranging from baby products to cold and cough treatments, vitamins, and digestive aids, catering to all age groups and providing comprehensive health care.
Commitment to China’s Health Goals
Huang Diren, General Manager of Teva Greater China, said, “With the continuous improvement of living standards and health awareness, the Chinese people’s pursuit of health has become more refined and diverse. We are very pleased to have reached strategic cooperation agreements with Zhejiang International Group and Jianmin International to bring high-quality products to Chinese consumers. Committed to ‘in China, for China,’ Teva will delve into the health needs of the Chinese people, continue to explore innovative cooperation models, and work with all parties to accelerate the introduction of more high-quality product portfolios, enhancing the health and well-being of the Chinese people and contributing to the ‘Healthy China’ initiative.”-Fineline Info & Tech
Leave a Reply